Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic therapeutics for life-threatening conditions. The company's pipeline consists primarily of two therapeutic candidates in development. INBRX-109 is a tetravalent therapeutic targeting death-receptor 5, currently being evaluated for unresectable or metastatic conventional chondrosarcoma. INBRX-106 is a hexavalent single-domain antibody-based therapeutic targeting OX40, being assessed across multiple solid tumor indications including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.

As a clinical-stage company, Inhibrx does not generate product revenues. The company operates with 156 full-time employees and is headquartered in La Jolla, California, with operations focused on research and clinical development activities. Inhibrx was incorporated in Delaware in 2024 and is publicly traded on the Nasdaq.